TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participant 18 years or over.~* Moderate (score=2) to severe (score=3) GFL at maximum frown as assessed by investigator on the 4-point facial wrinkle scale (FWS).~* Moderate (score=2) to severe (score=3) GFL at maximum frown as assessed by participant on the 4-point FWS.~Exclusion Criteria:~* Previous treatment with Botulinum neurotoxin (BoNT) of any serotype in the facial area within the last 12 months before injection.~* Previous treatment with any facial cosmetic procedure (example, chemical peeling, photo rejuvenation, mesotherapy, photodynamic therapy, laser treatment, tattooing of eyebrows) in the glabellar area within the last 12 months before injection.~* Previous treatment with any biodegradable filler in the glabellar area within the last 12 months before injection.~* Inability to substantially reduce GFL by physically spreading them apart as assessed by the investigator.~* Excessively thick sebaceous skin or hypertrophic muscles in the upper third part of the face.~* Any surgery or scars in the glabellar area.~* Marked facial asymmetry.~* Eyelid ptosis.~* Marked brow ptosis and/or dermatochalasis.~* Ongoing severe or unstable medical conditions, example, systemic infection, or pulmonary disease, at the discretion of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NT 201 Dose group 1 (Type: EXPERIMENTAL): Stage 1 and 2. Intramuscular injection into the glabellar area.
- NT 201 Dose group 2 (Type: EXPERIMENTAL): Stage 1. Intramuscular injection into the glabellar area.
- NT 201 Dose group 3 (Type: EXPERIMENTAL): Stage 1. Intramuscular injection into the glabellar area.
- NT 201 Dose group 4 (Type: EXPERIMENTAL): Stage 2. Intramuscular injection into the glabellar area.
- NT 201 Dose group 5 (Type: EXPERIMENTAL): Open Label Extension Period. Intramuscular injection into the glabellar area.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Decompensated Cirrhosis of liver.~Exclusion Criteria:~* Acute on chronic liver failure~* Spleen diameter of larger than 180 mm~* Diagnosis of concomitant hepatocellular carcinoma or other active malignancy~* Upper gastrointestinal bleed due to portal hypertension in the previous 7 days~* Recent episode of portal vein thrombosis~* Severe renal dysfunction creatinine (\>1.5mg/dl)~* Severe cardiac dysfunction~* Uncontrolled diabetes or diabetic retinopathy~* Acute infection or disseminate intravascular coagulation~* Active alcohol abuse in last 3months~* Known hypersensitivity to G-CSF and GH~* Human immunodeficiency virus seropositivity~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- standard medical therapy (Type: ACTIVE_COMPARATOR): Standard medical therapy
- G-CSF (Type: ACTIVE_COMPARATOR): Standard medical therapy plus G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year.
- G-CSF plus growth hormone (Type: ACTIVE_COMPARATOR): Standard medical therapy plus G-CSF plus Growth Hormone therapy. Growth Hormone will be given in low dose of 1unit sc daily for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who has received prime vaccination of adenovirus type-5 vectored COVID-19 vaccine~* Able to understand the content of informed consent and willing to sign the informed consent~* Negative in HIV diagnostic test.~* Axillary temperature ≤37.0°C.~* General good health as established by medical history and physical examination.~* Able to complete 12 months visit~Exclusion Criteria:~* Family history of seizure, epilepsy, brain or mental disease~* Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past.~* Woman who is pregnant, breast-feeding on day of enrollment, or become pregnant during the next 12 months~* Any acute fever disease or infections.~* History of SARS~* Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease.~* Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc.~* Hereditary angioneurotic edema or acquired angioneurotic edema~* Urticaria in last one year~* No spleen or functional spleen.~* Platelet disorder or other bleeding disorder may cause injection contraindication~* Faint at the sight of needles.~* Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months.~* Prior administration of blood products in last 4 months~* Prior administration of other research medicines in last 1 month~* Prior administration of attenuated vaccine in last 1 month~* Prior administration of inactivated vaccine in last 14 days~* Current anti-tuberculosis prophylaxis or therapy~* According to the judgement of investigator,various medical, psychological, social or other conditions, those could affect the subjects to sign informed consent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Adenovirus Type-5 Vectored COVID-19 Vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged ≥18 years.~* Diagnosis of chronic plaque psoriasis for ≥6 months before baseline.~* Candidates for phototherapy and/or systemic therapy.~* ≥10% body surface area (BSA) involvement at screening and baseline.~* static Physician's Global Assessment (sPGA) score ≥3, and Psoriasis Area and Severity Index (PASI) score ≥12 at screening and baseline.~Exclusion Criteria:~* Clinically significant flare of psoriasis during the 12 weeks before baseline.~* Systemic nonbiologic psoriasis therapy or phototherapy within 4 weeks. prior to baseline or topical psoriasis treatment or medicated shampoo within 2 weeks prior to baseline .~* Current or recent use of any biologic agent within the required washout periods.~* Clinical evidence or suspicion of active tuberculosis or previously had evidence of active tuberculosis and did not receive appropriate and documented treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab single dose (Type: EXPERIMENTAL): Participants received single dose of 80mg Ixekizumab by subcutaneous injection.
- Ixekizumab Multiple Regimen 1 (80mg Q2W) (Type: EXPERIMENTAL): Participants received multiple doses of Ixekizumab starting with 160mg initial dose followed by 80mg every two weeks (Q2W) by subcutaneous injection.
- Ixekizumab Multiple Regimen 2 (80mg Q4W) (Type: EXPERIMENTAL): Participants received multiple doses of 80mg Ixekizumab starting with 160mg initial dose followed by 80mg every four weeks (Q4W) by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* Clinical diagnosis of mild persistent asthma~* Pre-treatment with SABAs only~* FEV1 ≥80% predicted~* Good health with the exception of asthma~Main Exclusion Criteria:~* Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids~* COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in pulmonary function~* Pregnancy~* Intention to become pregnant during the course of the study~* Breast feeding~* Lack of safe contraception~* Current smokers ≥10 pack-years and ex-smokers with ≥10 pack-years

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Are the Cardiac Benefits of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients should meet the following inclusion criteria:~* Ambulatory patients age 18-85 years~* Diagnosis of Heart failure (NYHA II to III)~* LVEF\<50% on echocardiography or CMRI in the previous 6 months~* Have stable symptoms and therapy for HF within the last 3 months.~Exclusion Criteria:~* Pregnant or lactating women.~* Any history of diabetes by medical history or by any of the established criteria by the American Diabetes Association. It also includes patients with history of diabetes in remission.~* ACS or cardiac surgery within the last 3 months.~* Cancer or any other life-threatening condition.~* Pancreatitis.~* Glomerular Filtration Rate \< 45 ml/Kg/min.~* Use of continuous parental inotropic agents.~* Systolic BP \< 90 mm Hg.~* Psychiatric disease incompatible with being in study.~* Any contraindication to MRI procedures.~* Any other medical or physical condition considered to be inappropriate by a study physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): 10mg once a day
- Placebos (Type: PLACEBO_COMPARATOR): placebo once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Green Dot a Primary Prevention Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Only high school students attending the intervention or comparison high schools will be eligible. Two groups will be recruited: those receiving bystanding training and those not receiving such training who may or may not be in the social network of those receiving bystanding training.~Exclusion Criteria:~All other high school students in Kentucky

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- Green Dot Bystander Training (Type: EXPERIMENTAL): Green Dot intervention
- Control (Type: ACTIVE_COMPARATOR): Awareness Eduation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Ointment on Temporomandibular Joint and Masticatory Muscle Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Self report of facial ache or pain in the muscles of mastication, the TMJ, or the region in front of ear or inside the ear~2. Positive clinical diagnosis of TMDs. The TMD diagnosis is classified using axis I of the research diagnostic criteria ( RDC) for TMDs. The RDC diagnosis consists of joint pain at rest ( spontaneous pain) and evoked pain (hyperalgesia) on palpation of the TMJ, TMJ reduction consists of reciprocal clicking or joint noise with mandibular movement examination.~3. For joint pain complaint, subjects will be required to have a self-report of at least 1 month of daily or nearly-daily pain.~4. Subjects with myogenic pain will be included if they meet inclusion and exclusion criteria since patients with TMDs are known to exhibit muscle pain secondary to their joint dysfunction.~Exclusion Criteria:~1. Subjects with infectious arthritis, crystal induced arthropathies, musculoskeletal disorders, subjects with a primary diagnosis of myofascial pain based on the RDC;~2. Subjects with pain attributable to confirmed migraine or head pain condition other than tension headache;~3. Subjects with acute infection or other significant disease of teeth, ears, eyes, nose or throats; subjects with untreated depressive disorder or not on stable antidepressant medication for more than 6 months;~4. Subjects with dental diseases that required ongoing treatment, which would confound the evaluation of orofacial pain;~5. Subjects who are not competent in giving consents.~6. Pregnant or lactating women~7. Subjects with sensitivity to the ingredient of Ping On Ointment will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ping On Ointment (Type: EXPERIMENTAL): Ping On Ointment
- Vaseline (Type: PLACEBO_COMPARATOR): Vaseline with minor trace of Ping On ointment to give medicinal smell

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females between the ages of 18 and 80 years admitted to a general surgery service.~2. Patients admitted for non-cardiac elective or emergency surgery or trauma.~3. A known history of type 2 diabetes mellitus \> 3 months, receiving either diet alone or any combination of oral antidiabetic agents (sulfonylureas, metformin, thiazolidinediones).~4. Subjects must have an admission blood glucose \> 140 mg and \< 400 mg/dL without laboratory evidence of diabetic ketoacidosis (serum bicarbonate \< 18 mEq/L or positive serum or urinary ketones).~Exclusion Criteria:~1. Subjects with increased blood glucose concentration, but without a known history of diabetes (stress hyperglycemia).~2. Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria.~3. Acute critical illness or CABG surgery expected to require prolonged admission to a critical care unit (ICU, CCU, SICU, Neuro ICU).~4. Patients with clinically relevant hepatic disease or impaired renal function, as shown by a serum creatinine ≥ 3.5 mg/dl.~5. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.~6. Female subjects are pregnant or breast feeding at time of enrollment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Glargine once daily plus glulisine given before meals plus supplemental glulisine for BG \> 140
- 2 (Type: ACTIVE_COMPARATOR): Sliding scale regular insulin four-times daily achs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the HGS 1006-C1056 or HGS 1006-C1057 protocol through the Week 72 or Week 48 visits, respectively.~Exclusion Criteria:~* Have developed any other medical disease or condition that has made the patient unsuitable for this study in the opinion of their physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1 mg/kg dose of belimumab given IV every 28 days.
- 2. (Type: EXPERIMENTAL): 10 mg/kg dose of belimumab given IV every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of bullous or non bullous impetigo. The patient has a total affected area comprised between 1-100 cm2 with surrounding erythema not extending more than 2 cm from the edge of any affected area. In case of multiple affected areas the total area will be the sum of each affected area and will not exceed 100 cm2. Additionally for patients \< 12 years the total area will not exceed a maximum of 2% of the body surface area.~* Total Skin Infection Rating Scale (SIRS) score of at least 3, including pus/exudate score of at least 1~Exclusion Criteria:~* Has a bacterial infection, which in the opinion of the investigator, could not be appropriately treated by a topical antibiotic.~* Has systemic signs and symptoms of infection (e.g. a fever; defined as an axillary temperature over 37.2 °C (99.0 °F)

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ozenoxacin (Type: EXPERIMENTAL): ozenoxacin cream 1%
- Placebo (Type: PLACEBO_COMPARATOR): Placebo cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Trauma of Betrayal: Treating Adjustment Disorder With Reconsolidation Blockade Under Propranolol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of an adjustment disorder or chronic adjustment disorder, as defined by the Diagnostic and Statistical Manual for Mental Disorders, as a result of an attachment injury, defined as an event involving the perceived betrayal, violation of trust, or abandonment by a significant other.~* Currently experiencing clinically important psychological distress as a result of the event, as defined by a score of at least 22 on the IES-R, and a score of at least moderately ill on the Clinical Global Impressions - Severity of Illness Scale.~* Must have been in the romantic relationship for at least 6 months prior to the event.~* Must not take psychotropic medication.~* Fluency in English or French~Exclusion Criteria:~* Systolic blood pressure \<100 mm Hg;~* Cardiac rhythm below 55 beats per minute;~* A medical condition that contraindicates the administration of propranolol, e.g., Asthma, chronic obstructive pulmonary disease, cardiac insufficiency, cardiac choc, Second- or third-degree atrioventricular block, diabetes, spastic angina, auricular sinus illness, bradycardia, Raynaud's disease, severe peripheral vascular disease, untreated Pheochromocytoma, arterial hypotension, previous anaphylactic allergic shock;~* Previous adverse reaction to, or non-compliance with, beta-blocker;~* Current use of a substance that may involve potentially dangerous interactions with propranolol, including P450 2D6 inhibitors.~* Women who are pregnant or breast feeding;~* Individuals currently participating in any other form of psychotherapy (other than strictly supportive).~* History of substance dependence disorder, bipolar disorder, or psychotic disorder;~* Participants judged (based on history, mental status exam, clinical impression, or the Suicidal Behaviors Questionnaire as being at significant risk of suicidal behavior.~* Participation in another drug trial within 30 days prior to the screening visit~* Presence of any clinical condition that might interfere with the interpretation of the efficacy and safety results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Propranolol pill + mismatch memory reactivation (Type: EXPERIMENTAL): Prediction-error will be incorporated into each treatment sessions.
- Propranolol pill + standard memory reactivation (Type: EXPERIMENTAL): None
- Waitlist (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete